Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC 683864, IND 61010) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma.

Next Previous
Trial Profile

Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC 683864, IND 61010) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temsirolimus (Primary) ; Megestrol; Tamoxifen
  • Indications Endometrial cancer
  • Focus Therapeutic Use

Most Recent Events

  • 11 Apr 2017 Status changed from active, no longer recruiting to completed.
  • 02 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jan 2017.
  • 27 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed to 1 Jul 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top